Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline
Abstract Background Docosahexaenoic acid (DHA) plays an important role in neural function. Decreases in plasma DHA are associated with cognitive decline in healthy elderly adults and in patients with Alzheimer's disease. Higher DHA intake is inversely correlated with relative risk of Alzheimer&...
Saved in:
| Published in | Alzheimer's & dementia Vol. 6; no. 6; pp. 456 - 464 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Elsevier Inc
01.11.2010
The Alzheimer's Association |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Abstract Background Docosahexaenoic acid (DHA) plays an important role in neural function. Decreases in plasma DHA are associated with cognitive decline in healthy elderly adults and in patients with Alzheimer's disease. Higher DHA intake is inversely correlated with relative risk of Alzheimer's disease. The potential benefits of DHA supplementation in age-related cognitive decline (ARCD) have not been fully examined. Objective Determine effects of DHA administration on improving cognitive functions in healthy older adults with ARCD. Methods Randomized, double-blind, placebo-controlled, clinical study was conducted at 19 U.S. clinical sites. A total of 485 healthy subjects, aged ≥55 with Mini-Mental State Examination >26 and a Logical Memory (Wechsler Memory Scale III) baseline score ≥1 standard deviation below younger adults, were randomly assigned to 900 mg/d of DHA orally or matching placebo for 24 weeks. The primary outcome was the CANTAB Paired Associate Learning (PAL), a visuospatial learning and episodic memory test. Results Intention-to-treat analysis demonstrated significantly fewer PAL six pattern errors with DHA versus placebo at 24 weeks (difference score, −1.63 ± 0.76 [−3.1, −0.14, 95% CI], P = .03). DHA supplementation was also associated with improved immediate and delayed Verbal Recognition Memory scores ( P < .02), but not working memory or executive function tests. Plasma DHA levels doubled and correlated with improved PAL scores ( P < .02) in the DHA group. DHA was well tolerated with no reported treatment-related serious adverse events. Conclusions Twenty-four week supplementation with 900 mg/d DHA improved learning and memory function in ARCD and is a beneficial supplement that supports cognitive health with aging. Trial Registration Clinicaltrials.gov , Identifier: NCT0027813. |
|---|---|
| AbstractList | Docosahexaenoic acid (DHA) plays an important role in neural function. Decreases in plasma DHA are associated with cognitive decline in healthy elderly adults and in patients with Alzheimer's disease. Higher DHA intake is inversely correlated with relative risk of Alzheimer's disease. The potential benefits of DHA supplementation in age-related cognitive decline (ARCD) have not been fully examined.
Determine effects of DHA administration on improving cognitive functions in healthy older adults with ARCD.
Randomized, double-blind, placebo-controlled, clinical study was conducted at 19 U.S. clinical sites. A total of 485 healthy subjects, aged ≥55 with Mini-Mental State Examination >26 and a Logical Memory (Wechsler Memory Scale III) baseline score ≥1 standard deviation below younger adults, were randomly assigned to 900 mg/d of DHA orally or matching placebo for 24 weeks. The primary outcome was the CANTAB Paired Associate Learning (PAL), a visuospatial learning and episodic memory test.
Intention-to-treat analysis demonstrated significantly fewer PAL six pattern errors with DHA versus placebo at 24 weeks (difference score, −1.63 ± 0.76 [−3.1, −0.14, 95% CI],
P = .03). DHA supplementation was also associated with improved immediate and delayed Verbal Recognition Memory scores (
P < .02), but not working memory or executive function tests. Plasma DHA levels doubled and correlated with improved PAL scores (
P < .02) in the DHA group. DHA was well tolerated with no reported treatment-related serious adverse events.
Twenty-four week supplementation with 900 mg/d DHA improved learning and memory function in ARCD and is a beneficial supplement that supports cognitive health with aging.
Clinicaltrials.gov, Identifier: NCT0027813. Background Docosahexaenoic acid (DHA) plays an important role in neural function. Decreases in plasma DHA are associated with cognitive decline in healthy elderly adults and in patients with Alzheimer's disease. Higher DHA intake is inversely correlated with relative risk of Alzheimer's disease. The potential benefits of DHA supplementation in age‐related cognitive decline (ARCD) have not been fully examined. Objective Determine effects of DHA administration on improving cognitive functions in healthy older adults with ARCD. Methods Randomized, double‐blind, placebo‐controlled, clinical study was conducted at 19 U.S. clinical sites. A total of 485 healthy subjects, aged ≥55 with Mini‐Mental State Examination >26 and a Logical Memory (Wechsler Memory Scale III) baseline score ≥1 standard deviation below younger adults, were randomly assigned to 900 mg/d of DHA orally or matching placebo for 24 weeks. The primary outcome was the CANTAB Paired Associate Learning (PAL), a visuospatial learning and episodic memory test. Results Intention‐to‐treat analysis demonstrated significantly fewer PAL six pattern errors with DHA versus placebo at 24 weeks (difference score, −1.63 ± 0.76 [−3.1, −0.14, 95% CI], P = .03). DHA supplementation was also associated with improved immediate and delayed Verbal Recognition Memory scores (P < .02), but not working memory or executive function tests. Plasma DHA levels doubled and correlated with improved PAL scores (P < .02) in the DHA group. DHA was well tolerated with no reported treatment‐related serious adverse events. Conclusions Twenty‐four week supplementation with 900 mg/d DHA improved learning and memory function in ARCD and is a beneficial supplement that supports cognitive health with aging. Trial Registration Clinicaltrials.gov, Identifier: NCT0027813. Abstract Background Docosahexaenoic acid (DHA) plays an important role in neural function. Decreases in plasma DHA are associated with cognitive decline in healthy elderly adults and in patients with Alzheimer's disease. Higher DHA intake is inversely correlated with relative risk of Alzheimer's disease. The potential benefits of DHA supplementation in age-related cognitive decline (ARCD) have not been fully examined. Objective Determine effects of DHA administration on improving cognitive functions in healthy older adults with ARCD. Methods Randomized, double-blind, placebo-controlled, clinical study was conducted at 19 U.S. clinical sites. A total of 485 healthy subjects, aged ≥55 with Mini-Mental State Examination >26 and a Logical Memory (Wechsler Memory Scale III) baseline score ≥1 standard deviation below younger adults, were randomly assigned to 900 mg/d of DHA orally or matching placebo for 24 weeks. The primary outcome was the CANTAB Paired Associate Learning (PAL), a visuospatial learning and episodic memory test. Results Intention-to-treat analysis demonstrated significantly fewer PAL six pattern errors with DHA versus placebo at 24 weeks (difference score, −1.63 ± 0.76 [−3.1, −0.14, 95% CI], P = .03). DHA supplementation was also associated with improved immediate and delayed Verbal Recognition Memory scores ( P < .02), but not working memory or executive function tests. Plasma DHA levels doubled and correlated with improved PAL scores ( P < .02) in the DHA group. DHA was well tolerated with no reported treatment-related serious adverse events. Conclusions Twenty-four week supplementation with 900 mg/d DHA improved learning and memory function in ARCD and is a beneficial supplement that supports cognitive health with aging. Trial Registration Clinicaltrials.gov , Identifier: NCT0027813. Background Docosahexaenoic acid (DHA) plays an important role in neural function. Decreases in plasma DHA are associated with cognitive decline in healthy elderly adults and in patients with Alzheimer's disease. Higher DHA intake is inversely correlated with relative risk of Alzheimer's disease. The potential benefits of DHA supplementation in age-related cognitive decline (ARCD) have not been fully examined. Objective Determine effects of DHA administration on improving cognitive functions in healthy older adults with ARCD. Methods Randomized, double-blind, placebo-controlled, clinical study was conducted at 19 U.S. clinical sites. A total of 485 healthy subjects, aged >=55 with Mini-Mental State Examination >26 and a Logical Memory (Wechsler Memory Scale III) baseline score >=1 standard deviation below younger adults, were randomly assigned to 900 mg/d of DHA orally or matching placebo for 24 weeks. The primary outcome was the CANTAB Paired Associate Learning (PAL), a visuospatial learning and episodic memory test. Results Intention-to-treat analysis demonstrated significantly fewer PAL six pattern errors with DHA versus placebo at 24 weeks (difference score, -1.63 +/- 0.76 [-3.1, -0.14, 95% CI], P = .03). DHA supplementation was also associated with improved immediate and delayed Verbal Recognition Memory scores (P < .02), but not working memory or executive function tests. Plasma DHA levels doubled and correlated with improved PAL scores (P < .02) in the DHA group. DHA was well tolerated with no reported treatment-related serious adverse events. Conclusions Twenty-four week supplementation with 900 mg/d DHA improved learning and memory function in ARCD and is a beneficial supplement that supports cognitive health with aging. Trial Registration Clinicaltrials.gov, Identifier: NCT0027813. [Copyright Elsevier B.V.] Docosahexaenoic acid (DHA) plays an important role in neural function. Decreases in plasma DHA are associated with cognitive decline in healthy elderly adults and in patients with Alzheimer's disease. Higher DHA intake is inversely correlated with relative risk of Alzheimer's disease. The potential benefits of DHA supplementation in age-related cognitive decline (ARCD) have not been fully examined.BACKGROUNDDocosahexaenoic acid (DHA) plays an important role in neural function. Decreases in plasma DHA are associated with cognitive decline in healthy elderly adults and in patients with Alzheimer's disease. Higher DHA intake is inversely correlated with relative risk of Alzheimer's disease. The potential benefits of DHA supplementation in age-related cognitive decline (ARCD) have not been fully examined.Determine effects of DHA administration on improving cognitive functions in healthy older adults with ARCD.OBJECTIVEDetermine effects of DHA administration on improving cognitive functions in healthy older adults with ARCD.Randomized, double-blind, placebo-controlled, clinical study was conducted at 19 U.S. clinical sites. A total of 485 healthy subjects, aged ≥55 with Mini-Mental State Examination >26 and a Logical Memory (Wechsler Memory Scale III) baseline score ≥1 standard deviation below younger adults, were randomly assigned to 900 mg/d of DHA orally or matching placebo for 24 weeks. The primary outcome was the CANTAB Paired Associate Learning (PAL), a visuospatial learning and episodic memory test.METHODSRandomized, double-blind, placebo-controlled, clinical study was conducted at 19 U.S. clinical sites. A total of 485 healthy subjects, aged ≥55 with Mini-Mental State Examination >26 and a Logical Memory (Wechsler Memory Scale III) baseline score ≥1 standard deviation below younger adults, were randomly assigned to 900 mg/d of DHA orally or matching placebo for 24 weeks. The primary outcome was the CANTAB Paired Associate Learning (PAL), a visuospatial learning and episodic memory test.Intention-to-treat analysis demonstrated significantly fewer PAL six pattern errors with DHA versus placebo at 24 weeks (difference score, -1.63 ± 0.76 [-3.1, -0.14, 95% CI], P = .03). DHA supplementation was also associated with improved immediate and delayed Verbal Recognition Memory scores (P < .02), but not working memory or executive function tests. Plasma DHA levels doubled and correlated with improved PAL scores (P < .02) in the DHA group. DHA was well tolerated with no reported treatment-related serious adverse events.RESULTSIntention-to-treat analysis demonstrated significantly fewer PAL six pattern errors with DHA versus placebo at 24 weeks (difference score, -1.63 ± 0.76 [-3.1, -0.14, 95% CI], P = .03). DHA supplementation was also associated with improved immediate and delayed Verbal Recognition Memory scores (P < .02), but not working memory or executive function tests. Plasma DHA levels doubled and correlated with improved PAL scores (P < .02) in the DHA group. DHA was well tolerated with no reported treatment-related serious adverse events.Twenty-four week supplementation with 900 mg/d DHA improved learning and memory function in ARCD and is a beneficial supplement that supports cognitive health with aging.CONCLUSIONSTwenty-four week supplementation with 900 mg/d DHA improved learning and memory function in ARCD and is a beneficial supplement that supports cognitive health with aging.Clinicaltrials.gov, Identifier: NCT0027813.TRIAL REGISTRATIONClinicaltrials.gov, Identifier: NCT0027813. Docosahexaenoic acid (DHA) plays an important role in neural function. Decreases in plasma DHA are associated with cognitive decline in healthy elderly adults and in patients with Alzheimer's disease. Higher DHA intake is inversely correlated with relative risk of Alzheimer's disease. The potential benefits of DHA supplementation in age-related cognitive decline (ARCD) have not been fully examined. Determine effects of DHA administration on improving cognitive functions in healthy older adults with ARCD. Randomized, double-blind, placebo-controlled, clinical study was conducted at 19 U.S. clinical sites. A total of 485 healthy subjects, aged ≥55 with Mini-Mental State Examination >26 and a Logical Memory (Wechsler Memory Scale III) baseline score ≥1 standard deviation below younger adults, were randomly assigned to 900 mg/d of DHA orally or matching placebo for 24 weeks. The primary outcome was the CANTAB Paired Associate Learning (PAL), a visuospatial learning and episodic memory test. Intention-to-treat analysis demonstrated significantly fewer PAL six pattern errors with DHA versus placebo at 24 weeks (difference score, -1.63 ± 0.76 [-3.1, -0.14, 95% CI], P = .03). DHA supplementation was also associated with improved immediate and delayed Verbal Recognition Memory scores (P < .02), but not working memory or executive function tests. Plasma DHA levels doubled and correlated with improved PAL scores (P < .02) in the DHA group. DHA was well tolerated with no reported treatment-related serious adverse events. Twenty-four week supplementation with 900 mg/d DHA improved learning and memory function in ARCD and is a beneficial supplement that supports cognitive health with aging. Clinicaltrials.gov, Identifier: NCT0027813. |
| Author | Ryan, Alan S Blackwell, Andrew Yurko-Mauro, Karin Salem, Norman McCarthy, Deanna Rom, Dror Nelson, Edward B Stedman, Mary |
| Author_xml | – sequence: 1 fullname: Yurko-Mauro, Karin – sequence: 2 fullname: McCarthy, Deanna – sequence: 3 fullname: Rom, Dror – sequence: 4 fullname: Nelson, Edward B – sequence: 5 fullname: Ryan, Alan S – sequence: 6 fullname: Blackwell, Andrew – sequence: 7 fullname: Salem, Norman – sequence: 8 fullname: Stedman, Mary |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/20434961$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNUk2PFCEQJWaN-6F_wIPpm6ceoWloSIzJuPFrM4kHNTFeCEMXKy0Du9CzOv56wdndwx5WkwpUivdekXp1jA5CDIDQU4IXBBP-YlpM2v9edLgUMClBH6AjwljXsm6QB7c5x4foOOcJ4x4Lwh6hww73tJecHKGvryGAdcZp34C1YObcRNuM0cSsv8MvDSE602jjxiaGxsTz4GZXMhcafQ5tAq9nGG8erqAZwXgX4DF6aLXP8OT6PkFf3r75fPq-XX189-F0uWoN45y23AoGdNAwULzmQ0-5ZT3TAwDozpiejnyUWlgsBqmpNGvJekHpmgJIkFbQE_R8r3uR4uUW8qw2LhvwXgeI26xE1_VyEJz-EznIgmMcV-Sza-R2vYFRXSS30WmnbsZWAN0eYFLMOYG9hRCsqjdqUtUbVb1RmJSoquIOybhZ12HOSTt_P3W5p_50Hnb_0UwtV9_OzspRayX-arzca0Bx48pBUtk4CAZGl4rtaozu_i-8ukOvNjuj_Q_YQZ7iNoXisyIqdwqrT3X36uqV9nXvKP0DQIHR_w |
| CitedBy_id | crossref_primary_10_1007_s11101_013_9309_1 crossref_primary_10_1016_j_celrep_2018_10_078 crossref_primary_10_1002_ejlt_201300060 crossref_primary_10_1093_gerona_gly166 crossref_primary_10_7759_cureus_73390 crossref_primary_10_2196_ijmr_8981 crossref_primary_10_1016_j_pharmthera_2013_12_009 crossref_primary_10_1016_j_nbd_2015_09_002 crossref_primary_10_1146_annurev_nutr_012809_104635 crossref_primary_10_3233_JAD_191313 crossref_primary_10_1007_s12603_021_1723_2 crossref_primary_10_1016_j_jff_2020_104195 crossref_primary_10_1146_annurev_food_030216_030125 crossref_primary_10_12659_MSM_895381 crossref_primary_10_1016_j_plefa_2014_02_003 crossref_primary_10_1016_j_cnd_2013_03_004 crossref_primary_10_1016_j_plipres_2013_10_002 crossref_primary_10_1016_j_plipres_2023_101256 crossref_primary_10_3389_fnins_2021_736814 crossref_primary_10_1016_j_plipres_2023_101255 crossref_primary_10_1007_s12272_019_01168_3 crossref_primary_10_1186_s41110_016_0025_7 crossref_primary_10_1016_j_foodres_2022_111200 crossref_primary_10_1007_s11947_013_1147_z crossref_primary_10_1016_j_nut_2014_06_016 crossref_primary_10_1186_1471_2377_11_79 crossref_primary_10_1021_acs_jafc_5b02404 crossref_primary_10_3390_nu15132825 crossref_primary_10_1017_S0007114522001283 crossref_primary_10_1017_jns_2018_10 crossref_primary_10_1371_journal_pone_0186767 crossref_primary_10_1111_bcpt_12713 crossref_primary_10_1016_j_arr_2022_101835 crossref_primary_10_7759_cureus_30091 crossref_primary_10_3945_an_113_004556 crossref_primary_10_3389_fnagi_2024_1406079 crossref_primary_10_3390_foods11091215 crossref_primary_10_1111_nyas_13062 crossref_primary_10_1136_bmjopen_2018_024145 crossref_primary_10_1016_j_jpeds_2022_03_046 crossref_primary_10_1186_s12954_024_00993_0 crossref_primary_10_1038_jcbfm_2013_159 crossref_primary_10_1016_j_jff_2024_106369 crossref_primary_10_2460_javma_249_11_1267 crossref_primary_10_2217_clp_14_61 crossref_primary_10_3390_nu9050487 crossref_primary_10_1016_j_nut_2015_08_004 crossref_primary_10_1016_j_neuint_2013_02_016 crossref_primary_10_3390_nu16040489 crossref_primary_10_1038_s41430_017_0052_3 crossref_primary_10_3390_ani14131967 crossref_primary_10_1016_j_nbd_2022_105933 crossref_primary_10_3390_nu13082606 crossref_primary_10_1016_j_nut_2012_10_013 crossref_primary_10_1007_s11745_017_4292_8 crossref_primary_10_3390_ijms21249703 crossref_primary_10_3390_ijms22073574 crossref_primary_10_1016_j_archger_2024_105620 crossref_primary_10_1186_1476_511X_13_99 crossref_primary_10_3945_ajcn_110_007708 crossref_primary_10_1017_S0007114512001547 crossref_primary_10_1016_j_bbr_2016_07_043 crossref_primary_10_1179_1476830512Y_0000000025 crossref_primary_10_3390_nu8010006 crossref_primary_10_3389_fnagi_2017_00398 crossref_primary_10_1093_gerona_glv109 crossref_primary_10_1007_s13311_021_01170_y crossref_primary_10_1007_s10068_023_01465_0 crossref_primary_10_1192_bjp_2019_234 crossref_primary_10_3945_ajcn_113_074708 crossref_primary_10_1186_s12884_017_1244_5 crossref_primary_10_1080_07315724_2014_880660 crossref_primary_10_3389_fnagi_2018_00049 crossref_primary_10_29014_ns_2018_04 crossref_primary_10_1016_j_nut_2013_01_024 crossref_primary_10_1016_j_plefa_2017_08_001 crossref_primary_10_14283_jpad_2023_77 crossref_primary_10_1186_s12944_020_01337_0 crossref_primary_10_3390_biomedicines10081803 crossref_primary_10_1007_s12264_021_00814_5 crossref_primary_10_1016_j_arr_2016_08_008 crossref_primary_10_1016_j_ijdevneu_2019_10_004 crossref_primary_10_1016_j_ifset_2013_10_016 crossref_primary_10_1111_joim_12166 crossref_primary_10_1017_S000711451100403X crossref_primary_10_1016_j_plefa_2014_05_001 crossref_primary_10_3945_jn_114_193854 crossref_primary_10_1038_s42003_022_03169_3 crossref_primary_10_1002_ajpa_24820 crossref_primary_10_1007_s12603_014_0515_3 crossref_primary_10_1017_S0954422415000141 crossref_primary_10_1093_gerona_glt037 crossref_primary_10_1016_j_prostaglandins_2023_106733 crossref_primary_10_1590_1980_5764_dn_2022_0006 crossref_primary_10_1038_ejcn_2014_177 crossref_primary_10_3917_gs_134_0107 crossref_primary_10_3390_pharmaceutics15010082 crossref_primary_10_5650_jos_ess17035 crossref_primary_10_1111_nyas_13673 crossref_primary_10_1007_s40263_015_0256_9 crossref_primary_10_3390_ijms19071849 crossref_primary_10_3390_nu6104452 crossref_primary_10_1017_S0007114520002287 crossref_primary_10_3390_nu6093624 crossref_primary_10_3390_biom10020219 crossref_primary_10_1016_j_plefa_2017_01_011 crossref_primary_10_1016_j_exger_2016_08_004 crossref_primary_10_1194_jlr_R076331 crossref_primary_10_1016_j_plefa_2020_102159 crossref_primary_10_1016_j_plefa_2016_08_001 crossref_primary_10_1007_s12035_017_0413_x crossref_primary_10_1016_j_nupar_2011_09_004 crossref_primary_10_3945_an_113_005280 crossref_primary_10_1007_s12603_018_1052_2 crossref_primary_10_1111_j_1753_4887_2010_00345_x crossref_primary_10_1051_ocl_2011_0390 crossref_primary_10_3389_fnins_2022_1042865 crossref_primary_10_1186_s13024_018_0299_8 crossref_primary_10_1186_1475_2891_10_117 crossref_primary_10_1007_s00394_015_0890_5 crossref_primary_10_1016_j_clnu_2021_12_004 crossref_primary_10_1093_ajcn_nqab174 crossref_primary_10_1016_j_ctcp_2018_09_005 crossref_primary_10_1017_S0007114517003464 crossref_primary_10_1080_09637486_2017_1413640 crossref_primary_10_1002_gps_5707 crossref_primary_10_1016_j_ejphar_2011_07_011 crossref_primary_10_1080_10408398_2022_2092446 crossref_primary_10_1051_ocl_2012_0495 crossref_primary_10_3390_nu7085307 crossref_primary_10_3390_microbiolres14040127 crossref_primary_10_1007_s00253_019_09927_4 crossref_primary_10_1016_j_neubiorev_2020_12_022 crossref_primary_10_3945_ajcn_112_053371 crossref_primary_10_1001_jama_2019_22258 crossref_primary_10_1038_nrneurol_2015_177 crossref_primary_10_3389_fnut_2019_00110 crossref_primary_10_1039_D3FO02959J crossref_primary_10_4161_19490976_2014_983775 crossref_primary_10_1194_jlr_M042275 crossref_primary_10_1212_WNL_0b013e318249f6a9 crossref_primary_10_3233_JAD_150826 crossref_primary_10_3945_an_111_001693 crossref_primary_10_1186_1471_2202_14_77 crossref_primary_10_1111_nbu_12250 crossref_primary_10_3390_foods11131883 crossref_primary_10_5650_jos_ess21195 crossref_primary_10_1016_j_bbi_2020_09_022 crossref_primary_10_1080_21551197_2012_752335 crossref_primary_10_1002_hup_2520 crossref_primary_10_1016_j_clnesp_2022_12_004 crossref_primary_10_1186_s13195_016_0194_x crossref_primary_10_3390_nu10091253 crossref_primary_10_5937_arhfarm2002098Q crossref_primary_10_1093_nutrit_nuz073 crossref_primary_10_1111_jnc_12640 crossref_primary_10_1586_ern_12_43 crossref_primary_10_12968_bjnn_2014_10_1_29 crossref_primary_10_1016_j_neurobiolaging_2013_09_038 crossref_primary_10_1051_ocl_2018020 crossref_primary_10_2174_2210315512666220627153553 crossref_primary_10_1016_j_arr_2016_09_010 crossref_primary_10_1038_s41430_019_0544_4 crossref_primary_10_1038_s41598_020_67868_9 crossref_primary_10_1089_ars_2016_6958 crossref_primary_10_3390_ijms20092313 crossref_primary_10_1097_MCO_0b013e32835017cc crossref_primary_10_1111_j_1471_4159_2012_07772_x crossref_primary_10_1007_s11101_024_09942_y crossref_primary_10_1016_j_envres_2020_109627 crossref_primary_10_1002_bies_201800051 crossref_primary_10_1080_1028415X_2022_2055378 crossref_primary_10_1093_ajcn_nqaa420 crossref_primary_10_1007_s12603_017_0957_5 crossref_primary_10_1016_j_quascirev_2016_12_016 crossref_primary_10_3945_ajcn_114_095315 crossref_primary_10_3389_fnmol_2024_1424561 crossref_primary_10_1016_j_neurobiolaging_2022_05_008 crossref_primary_10_3390_nu14194136 crossref_primary_10_3945_an_111_000802 crossref_primary_10_1016_j_plefa_2014_10_003 crossref_primary_10_3389_fneur_2019_00642 crossref_primary_10_3390_app12157805 crossref_primary_10_1002_14651858_CD005379_pub3 crossref_primary_10_3233_JAD_180209 crossref_primary_10_1016_j_jand_2013_11_001 crossref_primary_10_2217_nnm_2019_0059 crossref_primary_10_1016_j_jnutbio_2016_03_002 crossref_primary_10_3390_nu6072730 crossref_primary_10_1371_journal_pone_0193568 crossref_primary_10_1080_03601277_2012_699838 crossref_primary_10_1016_j_jfca_2013_08_007 crossref_primary_10_1016_j_cnd_2014_03_003 crossref_primary_10_1016_j_nut_2018_04_006 crossref_primary_10_1016_j_trci_2018_10_005 crossref_primary_10_1016_j_eng_2023_04_012 crossref_primary_10_1017_S0954422416000184 crossref_primary_10_3945_ajcn_110_006320 crossref_primary_10_53841_bpsneur_2018_1_5_78 crossref_primary_10_1212_01_CON_0000396965_20811_df crossref_primary_10_1179_0001551213Z_0000000006 crossref_primary_10_1271_kagakutoseibutsu_61_196 crossref_primary_10_1007_s13668_020_00329_x crossref_primary_10_1016_j_ajcnut_2023_04_001 crossref_primary_10_1016_j_jnutbio_2013_09_015 crossref_primary_10_1186_s12916_024_03296_0 crossref_primary_10_3389_fnins_2021_613120 crossref_primary_10_1016_j_neurobiolaging_2011_12_014 crossref_primary_10_1016_j_jagp_2018_12_016 crossref_primary_10_1212_WNL_0b013e318264e394 crossref_primary_10_1093_aje_kwx330 crossref_primary_10_1016_j_plipres_2015_12_003 crossref_primary_10_1016_j_cger_2015_04_008 crossref_primary_10_3164_jcbn_24_36 crossref_primary_10_1016_j_eurger_2015_12_005 crossref_primary_10_1016_j_jlr_2023_100354 crossref_primary_10_1017_S0007114510005805 crossref_primary_10_1016_j_jnim_2016_05_002 crossref_primary_10_1177_1559827615579176 crossref_primary_10_3945_an_116_012187 crossref_primary_10_1016_j_med_2015_01_003 crossref_primary_10_1371_journal_pone_0093382 crossref_primary_10_1017_S0007114520000719 crossref_primary_10_1097_PSY_0000000000000104 crossref_primary_10_1016_j_bcab_2011_09_001 crossref_primary_10_1016_j_jnim_2015_04_001 crossref_primary_10_1096_fj_202300003R crossref_primary_10_1111_jhn_12335 crossref_primary_10_1186_s13104_019_4809_8 crossref_primary_10_3390_nu6125453 crossref_primary_10_1016_j_neurobiolaging_2018_05_017 crossref_primary_10_3390_ijms21165783 crossref_primary_10_1007_s12603_018_1028_2 crossref_primary_10_3390_nu16244344 crossref_primary_10_3233_RNN_201053 crossref_primary_10_1016_j_jamda_2020_02_022 crossref_primary_10_1371_journal_pone_0017397 crossref_primary_10_1177_1756286418791107 crossref_primary_10_1017_S0029665121003700 crossref_primary_10_1038_s41392_023_01486_5 crossref_primary_10_1017_S0029665113003625 crossref_primary_10_1016_j_procbio_2020_04_007 crossref_primary_10_1093_ijnp_pyw078 crossref_primary_10_7759_cureus_33982 crossref_primary_10_1007_s00429_013_0606_7 crossref_primary_10_1016_j_exger_2017_01_019 crossref_primary_10_1007_s11010_017_3061_6 crossref_primary_10_1080_1028415X_2019_1681088 crossref_primary_10_1016_j_neuropharm_2012_07_019 crossref_primary_10_1186_1475_2891_11_99 crossref_primary_10_3945_an_113_005264 crossref_primary_10_1002_hup_2694 crossref_primary_10_2903_j_efsa_2016_4455 crossref_primary_10_1080_13607863_2014_971705 crossref_primary_10_1017_S0317167100018497 crossref_primary_10_1155_2016_6462120 crossref_primary_10_1016_j_bbamem_2018_01_013 crossref_primary_10_1016_j_neuropharm_2015_05_013 crossref_primary_10_1017_S0029665114001426 crossref_primary_10_1016_j_tjnut_2024_09_015 crossref_primary_10_3390_jpm10020043 crossref_primary_10_1016_j_pbb_2012_07_009 crossref_primary_10_1089_act_2019_29230_klu crossref_primary_10_3233_JAD_150886 crossref_primary_10_1016_j_plefa_2014_01_002 crossref_primary_10_3390_membranes11120919 crossref_primary_10_1111_pbi_12012 crossref_primary_10_1080_14737175_2017_1326818 crossref_primary_10_1089_neu_2012_2672 crossref_primary_10_1007_s00394_021_02655_4 crossref_primary_10_3390_nu6051956 crossref_primary_10_1007_s40520_015_0381_9 crossref_primary_10_1016_j_bbr_2021_113207 crossref_primary_10_1016_j_neurobiolaging_2011_03_019 crossref_primary_10_1111_nure_12071 crossref_primary_10_1371_journal_pone_0048159 crossref_primary_10_3390_nu13020461 crossref_primary_10_3390_nu6104058 crossref_primary_10_14283_jpad_2020_9 crossref_primary_10_1016_j_avb_2019_101347 crossref_primary_10_1016_j_fct_2010_07_006 crossref_primary_10_3109_09637486_2014_979313 crossref_primary_10_1371_journal_pone_0120391 crossref_primary_10_3389_fnut_2022_852433 crossref_primary_10_1016_j_plefa_2022_102398 crossref_primary_10_1371_journal_pone_0281946 crossref_primary_10_1016_j_glohj_2020_01_004 crossref_primary_10_3233_JAD_231467 crossref_primary_10_1007_s00394_013_0561_3 crossref_primary_10_3390_md22030099 crossref_primary_10_1007_s12035_015_9392_y crossref_primary_10_1017_S0007114512004771 crossref_primary_10_1080_1028415X_2018_1500198 crossref_primary_10_5650_jos_ess15009 crossref_primary_10_3988_jcn_2018_14_1_29 crossref_primary_10_1016_S1474_4422_18_30338_7 crossref_primary_10_1016_j_bbamem_2013_12_016 crossref_primary_10_3233_JAD_220795 crossref_primary_10_1016_j_brainres_2023_148681 crossref_primary_10_1093_cercor_bht163 crossref_primary_10_3389_fnagi_2016_00038 crossref_primary_10_1016_j_plefa_2014_07_012 crossref_primary_10_3389_fnins_2018_00128 crossref_primary_10_1016_S1474_4422_15_00153_2 crossref_primary_10_3390_geriatrics1040029 crossref_primary_10_3390_md22100446 crossref_primary_10_1177_1178638817716457 crossref_primary_10_1371_journal_pone_0036861 crossref_primary_10_3389_fimmu_2017_01464 crossref_primary_10_1186_s13058_015_0571_6 crossref_primary_10_3390_nu15020464 crossref_primary_10_1016_j_regg_2023_101426 crossref_primary_10_1017_S0007114523002052 crossref_primary_10_3389_fnagi_2014_00282 crossref_primary_10_3389_fnagi_2024_1531278 crossref_primary_10_3390_nu8020099 crossref_primary_10_3390_healthcare3040898 crossref_primary_10_1016_j_biopha_2024_116467 crossref_primary_10_2903_j_efsa_2016_4539 crossref_primary_10_1111_nure_12094 crossref_primary_10_3233_JAD_180160 crossref_primary_10_1080_1028415X_2024_2404785 crossref_primary_10_1179_1476830511Y_0000000012 crossref_primary_10_56294_piii2024341 crossref_primary_10_3390_nu5072777 crossref_primary_10_1007_s11357_012_9453_3 crossref_primary_10_1371_journal_pone_0143135 crossref_primary_10_3945_ajcn_111_026435 crossref_primary_10_1016_j_plefa_2017_07_003 crossref_primary_10_3389_fncel_2019_00466 crossref_primary_10_2217_nmt_12_24 crossref_primary_10_1017_S0007114514000117 crossref_primary_10_1080_01616412_2019_1672381 crossref_primary_10_1007_s12603_012_0431_3 crossref_primary_10_1016_j_jpba_2025_116818 crossref_primary_10_2174_1570159X20666220830102628 crossref_primary_10_3390_nu3050529 crossref_primary_10_3233_JAD_150777 crossref_primary_10_1002_ejlt_201800524 crossref_primary_10_2217_nmt_11_61 crossref_primary_10_1016_j_tjnut_2024_01_012 crossref_primary_10_3390_nu8020086 crossref_primary_10_1016_j_algal_2020_101800 crossref_primary_10_1021_acs_langmuir_6b01984 crossref_primary_10_1080_07315724_2021_1962770 crossref_primary_10_1007_s12565_020_00574_8 crossref_primary_10_1016_S1474_4422_17_30040_6 crossref_primary_10_1111_bcp_12058 crossref_primary_10_3389_fncel_2014_00399 crossref_primary_10_1016_j_exger_2024_112520 crossref_primary_10_1007_s00228_020_02843_x crossref_primary_10_1016_j_clnu_2022_01_002 crossref_primary_10_1177_2156587213488788 crossref_primary_10_2174_1567205020666230609155932 crossref_primary_10_1111_jnc_16176 crossref_primary_10_1016_j_neurobiolaging_2016_02_007 crossref_primary_10_3390_nu11102279 crossref_primary_10_1016_j_jalz_2013_05_1771 crossref_primary_10_1017_S0007114511004089 crossref_primary_10_1080_10408398_2018_1425978 |
| Cites_doi | 10.1111/j.1365-2796.2006.01687.x 10.1001/archneur.63.10.1402 10.1016/S0006-8993(00)02115-6 10.1161/01.HYP.34.2.253 10.1016/S0163-7827(00)00017-5 10.1523/JNEUROSCI.4225-04.2005 10.1161/CIRCULATIONAHA.108.191261 10.1016/j.bandc.2005.10.004 10.1007/s11745-007-3098-5 10.1097/MJT.0b013e31817fe2be 10.1097/01.wad.0000213873.25053.2b 10.1016/0022-3956(82)90033-4 10.1159/000051269 10.7326/0003-4819-148-6-200803180-00005 10.1093/ajcn/85.4.1103 10.1016/j.jalz.2008.07.003 10.1080/13607860410001709665 10.1159/000074081 10.1093/ajcn/83.6.1467S 10.1093/gerona/63.11.1153 10.1080/87565648609540348 10.1212/01.wnl.0000324268.45138.86 10.1054/plef.2002.0408 10.1212/01.WNL.0000103860.75218.A5 10.1093/ajcn/77.4.803 10.1007/s11745-001-0805-6 10.1016/j.pnpbp.2008.05.015 10.1017/S003329170200524X 10.1523/JNEUROSCI.0055-07.2007 10.1002/ana.10105 10.1017/S1355617702811067 10.1001/archneur.60.7.940 10.1007/s11745-000-0646-3 10.1001/archneur.63.11.1545 10.1016/j.pnpbp.2007.01.011 10.1016/0022-3956(75)90026-6 |
| ContentType | Journal Article |
| Contributor | Kirby, Louis Arguello, Fares Geohas, Jeff Moldauer, Leslie Griffin, Carl Galef, Franklin McElveen, William Stedman, Mary Thein, Stephen Brody, Mark Edwards, Keith Berwald, Bruce Weiss, Thomas Winston, Jaron Lefebvre, Gigi McCarthy, Craig Goldstein, Jerome Kalafer, Marvin Sheftell, Fred |
| Contributor_xml | – sequence: 1 givenname: Fares surname: Arguello fullname: Arguello, Fares – sequence: 2 givenname: Bruce surname: Berwald fullname: Berwald, Bruce – sequence: 3 givenname: Mark surname: Brody fullname: Brody, Mark – sequence: 4 givenname: Keith surname: Edwards fullname: Edwards, Keith – sequence: 5 givenname: Franklin surname: Galef fullname: Galef, Franklin – sequence: 6 givenname: Jeff surname: Geohas fullname: Geohas, Jeff – sequence: 7 givenname: Jerome surname: Goldstein fullname: Goldstein, Jerome – sequence: 8 givenname: Carl surname: Griffin fullname: Griffin, Carl – sequence: 9 givenname: Marvin surname: Kalafer fullname: Kalafer, Marvin – sequence: 10 givenname: Louis surname: Kirby fullname: Kirby, Louis – sequence: 11 givenname: Gigi surname: Lefebvre fullname: Lefebvre, Gigi – sequence: 12 givenname: Craig surname: McCarthy fullname: McCarthy, Craig – sequence: 13 givenname: William surname: McElveen fullname: McElveen, William – sequence: 14 givenname: Leslie surname: Moldauer fullname: Moldauer, Leslie – sequence: 15 givenname: Fred surname: Sheftell fullname: Sheftell, Fred – sequence: 16 givenname: Mary surname: Stedman fullname: Stedman, Mary – sequence: 17 givenname: Stephen surname: Thein fullname: Thein, Stephen – sequence: 18 givenname: Thomas surname: Weiss fullname: Weiss, Thomas – sequence: 19 givenname: Jaron surname: Winston fullname: Winston, Jaron |
| Copyright | The Alzheimer's Association 2010 The Alzheimer's Association Copyright © 2010 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved. |
| Copyright_xml | – notice: The Alzheimer's Association – notice: 2010 The Alzheimer's Association – notice: Copyright © 2010 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved. |
| CorporateAuthor | on behalf of the MIDAS Investigators MIDAS Investigators |
| CorporateAuthor_xml | – name: on behalf of the MIDAS Investigators – name: MIDAS Investigators |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 7QJ |
| DOI | 10.1016/j.jalz.2010.01.013 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Applied Social Sciences Index & Abstracts (ASSIA) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic Applied Social Sciences Index and Abstracts (ASSIA) |
| DatabaseTitleList | Applied Social Sciences Index and Abstracts (ASSIA) MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| EISSN | 1552-5279 |
| EndPage | 464 |
| ExternalDocumentID | 20434961 10_1016_j_jalz_2010_01_013 ALZJJALZ201001013 S1552526010000403 1_s2_0_S1552526010000403 |
| Genre | article Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- --K --M .~1 0R~ 1B1 1OC 1~. 1~5 24P 33P 4.4 457 4G. 53G 5VS 7-5 71M 7RV 7X7 8FI 8FJ 8P~ AACTN AAEDT AAHHS AAIKJ AAKOC AALRI AANLZ AAOAW AAXLA AAXUO AAYCA ABBQC ABCQJ ABCUV ABIVO ABJNI ABMAC ABMZM ABUWG ABWVN ACCFJ ACCMX ACCZN ACGFS ACGOF ACPOU ACRPL ACXQS ADBBV ADBTR ADEZE ADHUB ADKYN ADMUD ADNMO ADPDF ADVLN ADZMN ADZOD AEEZP AEIGN AEKER AENEX AEQDE AEUYR AEVXI AFKRA AFTJW AFWVQ AGHFR AGUBO AGWIK AGYEJ AITUG AIURR AIWBW AJBDE AJOXV AJRQY AKRWK ALMA_UNASSIGNED_HOLDINGS ALUQN AMFUW AMRAJ AMYDB ANZVX AZQEC BENPR BFHJK BLXMC C45 CCPQU DCZOG EBS EJD EMOBN EO8 EO9 EP2 EP3 F5P FDB FEDTE FIRID FNPLU FYUFA G-Q GBLVA HMCUK HVGLF HX~ HZ~ IHE J1W K9- LATKE LEEKS M0R M41 MO0 MOBAO N9A NAPCQ O-L O9- OAUVE OVD OVEED OZT P-8 P-9 P2P PC. PGMZT PIMPY PSYQQ Q38 QTD RIG ROL RPM RPZ SDF SDG SEL SES SSZ SUPJJ T5K TEORI UKHRP ~G- AAQFI ABYKQ AJBFU EFLBG LCYCR WXSBR AAYWO AAYXX ACVFH ADCNI AEUPX AFPUW AGHNM AIGII AKBMS AKYEP CITATION PHGZM PHGZT CGR CUY CVF ECM EIF NPM 7X8 AAMMB AEFGJ AGXDD AIDQK AIDYY 7QJ |
| ID | FETCH-LOGICAL-c5663-6f85e37ae730b67436f545a7eeea2cc43d6d9a8f0879a39cb954833b3ee9e9f83 |
| IEDL.DBID | .~1 |
| ISSN | 1552-5260 1552-5279 |
| IngestDate | Fri Jul 11 12:29:20 EDT 2025 Thu Jul 10 22:52:29 EDT 2025 Thu Apr 03 06:59:14 EDT 2025 Thu Apr 24 22:51:20 EDT 2025 Tue Jul 01 00:24:18 EDT 2025 Wed Jan 22 16:35:34 EST 2025 Fri Feb 23 02:22:23 EST 2024 Sun Feb 23 10:18:56 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | clinical trial nutrition memory omega-3 fatty acid cognition docosahexaenoic acid learning aging |
| Language | English |
| License | Copyright © 2010 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5663-6f85e37ae730b67436f545a7eeea2cc43d6d9a8f0879a39cb954833b3ee9e9f83 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| PMID | 20434961 |
| PQID | 799785603 |
| PQPubID | 23479 |
| PageCount | 9 |
| ParticipantIDs | proquest_miscellaneous_822497863 proquest_miscellaneous_799785603 pubmed_primary_20434961 crossref_primary_10_1016_j_jalz_2010_01_013 crossref_citationtrail_10_1016_j_jalz_2010_01_013 wiley_primary_10_1016_j_jalz_2010_01_013_ALZJJALZ201001013 elsevier_sciencedirect_doi_10_1016_j_jalz_2010_01_013 elsevier_clinicalkeyesjournals_1_s2_0_S1552526010000403 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | November 2010 |
| PublicationDateYYYYMMDD | 2010-11-01 |
| PublicationDate_xml | – month: 11 year: 2010 text: November 2010 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Alzheimer's & dementia |
| PublicationTitleAlternate | Alzheimers Dement |
| PublicationYear | 2010 |
| Publisher | Elsevier Inc The Alzheimer's Association |
| Publisher_xml | – name: Elsevier Inc – name: The Alzheimer's Association |
| References | Lim, Calon, Morihara, Yang, Teter, Ubeda (bib15) 2005; 25 Morris, Evans, Bienias, Tangney, Bennett, Wilson (bib8) 2003; 60 Blackwell, Sahakian, Vesey, Semple, Robbins, Hodges (bib40) 2004; 17 Heude, Ducimetiere, Berr (bib3) 2003; 77 Galasko, Bennett, Sano, Marson, Kaye, Edland (bib33) 2006; 20 Accessed February 15, 2005. Fowler, Saling, Conway, Semple, Louis (bib39) 2002; 8 Ryan, Keske, Hoffman, Nelson (bib30) 2009; 16 Mori, Bao, Burke, Puddey, Beilin (bib43) 1999; 34 Tsukada, Kakiuchi, Fukumoto, Nishiyama, Koga (bib13) 2000; 862 (bib26) 1994 Conquer, Tierney, Zecevic, Bettger, Fisher (bib5) 2000; 35 Arterburn, Hall, Oken (bib29) 2006; 83 Lauritzen, Hansen, Jorgensen, Michaelsen (bib10) 2001; 40 Freund-Levi, Eriksdotter-Jonhagen, Cederholm, Basun, Faxen-Irving, Garlind (bib19) 2006; 63 Chiu, Su, Cheng, Liu, Chang, Dewey (bib18) 2008; 32 FDA. Agency Response Letter Gras Notification No. GRN000137; February 12 2004. Stampfer (bib42) 2006; 260 Cargin, Maruff, Collie, Masters (bib23) 2006; 60 Folstein, Folstein, McHugh (bib34) 1975; 12 Accessed December 17, 2007 Salem, Litman, Kim, Gawrisch (bib11) 2001; 36 Egerhazi, Berecz, Bartok, Degrell (bib25) 2007; 31 Arterburn, Oken, Hoffman, Bailey-Hall, Chung, Rom (bib36) 2007; 42 Schaefer, Bongard, Beiser, Lamon-Fava, Robins, Au (bib6) 2006; 63 Noel, Hoffman, Ellis, Yurko-Mauro, Cella, Sercus (bib7) 2006; 11 Lloyd-Jones, Adams, Carnethon, De Simone, Ferguson, Flegal (bib38) 2009; 119 Robbins, James, Owen, Sahakian, McInnes, Rabbitt (bib21) 1994; 5 Beydoun, Kaufman, Satia, Rosamond, Folsom (bib4) 2007; 85 Small, Tsai, DeLaPaz, Mayeux, Stern (bib24) 2002; 51 de Jager, Milwain, Budge (bib22) 2002; 32 USDA. Nutrient intakes from food: mean amounts consumed per individual, one day, 2003-2004. USDA, Agricultural Research Service, 2007. Available at Green, Martinez-Coria, Khashwji, Hall, Yurko-Mauro, Ellis (bib16) 2007; 27 Wild, Howieson, Webbe, Seelye, Kaye (bib20) 2008; 4 Kalmijn, van Boxtel, Ocke, Verschuren, Kromhout, Launer (bib9) 2004; 62 van de Rest, Geleijnse, Kok, van Staveren, Dullemeijer, Olderikkert (bib17) 2008; 71 Zelinski, Gilewski (bib32) 2004; 8 Swainson, Hodges, Galton, Semple, Michael, Dunn (bib41) 2001; 12 Benisek D, Bailey-Hall E, Oken H, Masayesva S, Arterburn L. Validation of a simple food frequency questionnaire as an indicator of long chain omega-3 intake. In: Inform 2002; Abstracts of the 93rd Annual AOCS Meeting and Expo; 2002; Montreal, Quebec, Canada:S96. Yesavage, Brink, Rose, Lum, Huang, Adey (bib35) 1982; 17 Alzheimer's Association. Alzheimer's disease and maintaining brain and memory health national survey results, 2004. Available at Petursdottir, Farr, Morley, Banks, Skuladottir (bib14) 2008; 63 Martin, Spencer, Horrobin, Lynch (bib12) 2002; 67 Crook, Bartus, Ferris, Whitehouse, Cohen, Gerston (bib27) 1986; 2 Plassman, Langa, Fisher, Heeringa, Weir, Ofstedal (bib2) 2008; 148 2004; 62 1982; 17 2006; 11 2002; 51 2004; 8 2002; 32 2002; 8 1975; 12 2008; 32 1994 2008; 148 2008; 4 2007; 31 2009; 119 2008; 71 2001; 40 2003; 77 2005; 25 2006; 60 1986; 2 2006; 63 2006; 20 2006; 83 2000; 862 2000; 35 2004; 17 2002; 67 1999; 34 2008; 63 2006; 260 2007; 85 2003; 60 2007; 42 2001; 12 2001; 36 1994; 5 2009; 16 2007; 27 e_1_2_6_31_2 Arterburn L.M. (e_1_2_6_30_2) 2006; 83 e_1_2_6_18_2 e_1_2_6_19_2 e_1_2_6_12_2 e_1_2_6_35_2 e_1_2_6_13_2 e_1_2_6_34_2 e_1_2_6_10_2 e_1_2_6_33_2 e_1_2_6_11_2 e_1_2_6_32_2 e_1_2_6_16_2 e_1_2_6_39_2 e_1_2_6_17_2 e_1_2_6_38_2 e_1_2_6_14_2 e_1_2_6_37_2 e_1_2_6_15_2 e_1_2_6_36_2 e_1_2_6_42_2 e_1_2_6_20_2 American Psychiatric Association (e_1_2_6_27_2) 1994 e_1_2_6_41_2 Robbins T.W. (e_1_2_6_22_2) 1994; 5 e_1_2_6_40_2 e_1_2_6_7_2 e_1_2_6_9_2 Cargin J.W. (e_1_2_6_24_2) 2006; 60 e_1_2_6_29_2 e_1_2_6_4_2 e_1_2_6_3_2 e_1_2_6_6_2 Noel K. (e_1_2_6_8_2) 2006; 11 e_1_2_6_5_2 e_1_2_6_23_2 e_1_2_6_2_2 e_1_2_6_21_2 e_1_2_6_28_2 e_1_2_6_43_2 e_1_2_6_44_2 e_1_2_6_26_2 e_1_2_6_25_2 |
| References_xml | – volume: 31 start-page: 746 year: 2007 end-page: 751 ident: bib25 article-title: Automated Neuropsychological Test Battery (CANTAB) in mild cognitive impairment and in Alzheimer's disease publication-title: Prog Neuropsychopharmacol Biol Psychiatry – volume: 12 start-page: 189 year: 1975 end-page: 198 ident: bib34 article-title: “Mini-mental state". A practical method for grading the cognitive state of patients for the clinician publication-title: J Psychiatr Res – volume: 862 start-page: 180 year: 2000 end-page: 186 ident: bib13 article-title: Docosahexaenoic acid (DHA) improves the age-related impairment of the coupling mechanism between neuronal activation and functional cerebral blood flow response: a PET study in conscious monkeys publication-title: Brain Res – volume: 32 start-page: 1538 year: 2008 end-page: 1544 ident: bib18 article-title: The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study publication-title: Prog Neuropsychopharmacol Biol Psychiatry – volume: 34 start-page: 253 year: 1999 end-page: 260 ident: bib43 article-title: Docosahexaenoic acid but not eicosapentaenoic acid lowers ambulatory blood pressure and heart rate in humans publication-title: Hypertension – volume: 77 start-page: 803 year: 2003 end-page: 808 ident: bib3 article-title: Cognitive decline and fatty acid composition of erythrocyte membranes—The EVA study publication-title: Am J Clin Nutr – volume: 83 year: 2006 ident: bib29 article-title: Distribution, interconversion, and dose response of n-3 fatty acids in humans publication-title: Am J Clin Nutr – volume: 17 start-page: 42 year: 2004 end-page: 48 ident: bib40 article-title: Detecting dementia: novel neuropsychological markers of preclinical Alzheimer's disease publication-title: Dement Geriatr Cogn Disord – volume: 8 start-page: 58 year: 2002 end-page: 71 ident: bib39 article-title: Paired associate performance in the early detection of DAT publication-title: J Int Neuropsychol Soc – volume: 25 start-page: 3032 year: 2005 end-page: 3040 ident: bib15 article-title: A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model publication-title: J Neurosci – volume: 17 start-page: 37 year: 1982 end-page: 49 ident: bib35 article-title: Development and validation of a geriatric depression screening scale: a preliminary report publication-title: J Psychiatr Res – reference: . Accessed February 15, 2005. – volume: 60 start-page: 146 year: 2006 end-page: 155 ident: bib23 article-title: Mild memory impairment in healthy older adults is distinct from normal aging publication-title: Brain Cogn – volume: 40 start-page: 1 year: 2001 end-page: 94 ident: bib10 article-title: The essentiality of long chain n-3 fatty acids in relation to development and function of the brain and retina publication-title: Prog Lipid Res – reference: Benisek D, Bailey-Hall E, Oken H, Masayesva S, Arterburn L. Validation of a simple food frequency questionnaire as an indicator of long chain omega-3 intake. In: Inform 2002; Abstracts of the 93rd Annual AOCS Meeting and Expo; 2002; Montreal, Quebec, Canada:S96. – volume: 35 start-page: 1305 year: 2000 end-page: 1312 ident: bib5 article-title: Fatty acid analysis of blood plasma of patients with Alzheimer's disease, other types of dementia, and cognitive impairment publication-title: Lipids – volume: 63 start-page: 1545 year: 2006 end-page: 1550 ident: bib6 article-title: Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study publication-title: Arch Neurol – reference: Alzheimer's Association. Alzheimer's disease and maintaining brain and memory health national survey results, 2004. Available at – volume: 71 start-page: 430 year: 2008 end-page: 438 ident: bib17 article-title: Effect of fish oil on cognitive performance in older subjects: a randomized, controlled trial publication-title: Neurology – volume: 12 start-page: 265 year: 2001 end-page: 280 ident: bib41 article-title: Early detection and differential diagnosis of Alzheimer's disease and depression with neuropsychological tasks publication-title: Dement Geriatr Cogn Disord – volume: 260 start-page: 211 year: 2006 end-page: 223 ident: bib42 article-title: Cardiovascular disease and Alzheimer's disease: common links publication-title: J Intern Med – volume: 36 start-page: 945 year: 2001 end-page: 959 ident: bib11 article-title: Mechanisms of action of docosahexaenoic acid in the nervous system publication-title: Lipids – volume: 42 start-page: 1011 year: 2007 end-page: 1024 ident: bib36 article-title: Bioequivalence of docosahexaenoic acid from different algal oils in capsules and in a DHA-fortified food publication-title: Lipids – reference: . Accessed December 17, 2007 – volume: 119 start-page: e21 year: 2009 end-page: e181 ident: bib38 article-title: Heart Disease and Stroke Statistics—2009 Update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee publication-title: Circulation – volume: 62 start-page: 275 year: 2004 end-page: 280 ident: bib9 article-title: Dietary intake of fatty acids and fish in relation to cognitive performance at middle age publication-title: Neurology – volume: 27 start-page: 4385 year: 2007 end-page: 4395 ident: bib16 article-title: Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid-beta and tau pathology via a mechanism involving presenilin 1 levels publication-title: J Neurosci – volume: 8 start-page: 293 year: 2004 end-page: 306 ident: bib32 article-title: A 10-item Rasch modeled memory self-efficacy scale publication-title: Aging Ment Health – volume: 5 start-page: 266 year: 1994 end-page: 281 ident: bib21 article-title: Cambridge Neuropsychological Test Automated Battery (CANTAB): a factor analytic study of a large sample of normal elderly volunteers publication-title: Dementia – volume: 63 start-page: 1153 year: 2008 end-page: 1160 ident: bib14 article-title: Effect of dietary n-3 polyunsaturated fatty acids on brain lipid fatty acid composition, learning ability, and memory of senescence-accelerated mouse publication-title: J Gerontol A Biol Sci Med Sci – volume: 67 start-page: 121 year: 2002 end-page: 130 ident: bib12 article-title: Long-term potentiation in aged rats is restored when the age-related decrease in polyunsaturated fatty acid concentration is reversed publication-title: Prostaglandins Leukot Essent Fatty Acids – volume: 2 start-page: 261 year: 1986 end-page: 276 ident: bib27 article-title: Age associated memory impairment: proposed diagnostic criteria publication-title: Dev Neuropsychol – volume: 148 start-page: 427 year: 2008 end-page: 434 ident: bib2 article-title: Prevalence of cognitive impairment without dementia in the United States publication-title: Ann Intern Med – volume: 32 start-page: 483 year: 2002 end-page: 491 ident: bib22 article-title: Early detection of isolated memory deficits in the elderly: the need for more sensitive neuropsychological tests publication-title: Psychol Med – volume: 11 start-page: 381 year: 2006 end-page: 387 ident: bib7 article-title: DHA and cognitive function in the elderly: a systematic review of the literature publication-title: Res Pract Alzheimer's Dis – volume: 60 start-page: 940 year: 2003 end-page: 946 ident: bib8 article-title: Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease publication-title: Arch Neurol – volume: 16 start-page: 183 year: 2009 end-page: 192 ident: bib30 article-title: Clinical overview of algal-docosahexaenoic acid: effects on triglyceride levels and other cardiovascular risk factors publication-title: Am J Ther – reference: USDA. Nutrient intakes from food: mean amounts consumed per individual, one day, 2003-2004. USDA, Agricultural Research Service, 2007. Available at – volume: 85 start-page: 1103 year: 2007 end-page: 1111 ident: bib4 article-title: Plasma n-3 fatty acids and the risk of cognitive decline in older adults: the Atherosclerosis Risk in Communities Study publication-title: Am J Clin Nutr – volume: 20 start-page: S152 year: 2006 end-page: S169 ident: bib33 article-title: ADCS Prevention Instrument Project: assessment of instrumental activities of daily living for community-dwelling elderly individuals in dementia prevention clinical trials publication-title: Alzheimer Dis Assoc Disord – volume: 63 start-page: 1402 year: 2006 end-page: 1408 ident: bib19 article-title: Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial publication-title: Arch Neurol – volume: 51 start-page: 290 year: 2002 end-page: 295 ident: bib24 article-title: Imaging hippocampal function across the human life span: is memory decline normal or not? publication-title: Ann Neurol – reference: FDA. Agency Response Letter Gras Notification No. GRN000137; February 12 2004. – year: 1994 ident: bib26 article-title: Diagnostic and Statistical Manual of Mental Disorders – volume: 4 start-page: 428 year: 2008 end-page: 437 ident: bib20 article-title: Status of computerized cognitive testing in aging: a systematic review publication-title: Alzheimer's Dement – volume: 8 start-page: 293 year: 2004 end-page: 306 article-title: A 10‐item Rasch modeled memory self‐efficacy scale publication-title: Aging Ment Health – volume: 35 start-page: 1305 year: 2000 end-page: 1312 article-title: Fatty acid analysis of blood plasma of patients with Alzheimer's disease, other types of dementia, and cognitive impairment publication-title: Lipids – volume: 63 start-page: 1402 year: 2006 end-page: 1408 article-title: Omega‐3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double‐blind trial publication-title: Arch Neurol – volume: 40 start-page: 1 year: 2001 end-page: 94 article-title: The essentiality of long chain n‐3 fatty acids in relation to development and function of the brain and retina publication-title: Prog Lipid Res – volume: 16 start-page: 183 year: 2009 end-page: 192 article-title: Clinical overview of algal‐docosahexaenoic acid: effects on triglyceride levels and other cardiovascular risk factors publication-title: Am J Ther – volume: 5 start-page: 266 year: 1994 end-page: 281 article-title: Cambridge Neuropsychological Test Automated Battery (CANTAB): a factor analytic study of a large sample of normal elderly volunteers publication-title: Dementia – volume: 32 start-page: 483 year: 2002 end-page: 491 article-title: Early detection of isolated memory deficits in the elderly: the need for more sensitive neuropsychological tests publication-title: Psychol Med – volume: 60 start-page: 146 year: 2006 end-page: 155 article-title: Mild memory impairment in healthy older adults is distinct from normal aging publication-title: Brain Cogn – volume: 2 start-page: 261 year: 1986 end-page: 276 article-title: Age associated memory impairment: proposed diagnostic criteria publication-title: Dev Neuropsychol – volume: 34 start-page: 253 year: 1999 end-page: 260 article-title: Docosahexaenoic acid but not eicosapentaenoic acid lowers ambulatory blood pressure and heart rate in humans publication-title: Hypertension – volume: 20 start-page: S152 year: 2006 end-page: S169 article-title: ADCS Prevention Instrument Project: assessment of instrumental activities of daily living for community‐dwelling elderly individuals in dementia prevention clinical trials publication-title: Alzheimer Dis Assoc Disord – volume: 36 start-page: 945 year: 2001 end-page: 959 article-title: Mechanisms of action of docosahexaenoic acid in the nervous system publication-title: Lipids – volume: 27 start-page: 4385 year: 2007 end-page: 4395 article-title: Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid‐beta and tau pathology via a mechanism involving presenilin 1 levels publication-title: J Neurosci – volume: 8 start-page: 58 year: 2002 end-page: 71 article-title: Paired associate performance in the early detection of DAT publication-title: J Int Neuropsychol Soc – volume: 4 start-page: 428 year: 2008 end-page: 437 article-title: Status of computerized cognitive testing in aging: a systematic review publication-title: Alzheimer's Dement – year: 1994 – volume: 32 start-page: 1538 year: 2008 end-page: 1544 article-title: The effects of omega‐3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double‐blind placebo‐controlled study publication-title: Prog Neuropsychopharmacol Biol Psychiatry – volume: 17 start-page: 42 year: 2004 end-page: 48 article-title: Detecting dementia: novel neuropsychological markers of preclinical Alzheimer's disease publication-title: Dement Geriatr Cogn Disord – volume: 119 start-page: e21 year: 2009 end-page: e181 article-title: Heart Disease and Stroke Statistics—2009 Update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee publication-title: Circulation – volume: 60 start-page: 940 year: 2003 end-page: 946 article-title: Consumption of fish and n‐3 fatty acids and risk of incident Alzheimer disease publication-title: Arch Neurol – volume: 51 start-page: 290 year: 2002 end-page: 295 article-title: Imaging hippocampal function across the human life span: is memory decline normal or not? publication-title: Ann Neurol – volume: 83 year: 2006 article-title: Distribution, interconversion, and dose response of n‐3 fatty acids in humans publication-title: Am J Clin Nutr – volume: 148 start-page: 427 year: 2008 end-page: 434 article-title: Prevalence of cognitive impairment without dementia in the United States publication-title: Ann Intern Med – volume: 85 start-page: 1103 year: 2007 end-page: 1111 article-title: Plasma n‐3 fatty acids and the risk of cognitive decline in older adults: the Atherosclerosis Risk in Communities Study publication-title: Am J Clin Nutr – volume: 25 start-page: 3032 year: 2005 end-page: 3040 article-title: A diet enriched with the omega‐3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model publication-title: J Neurosci – volume: 12 start-page: 189 year: 1975 end-page: 198 article-title: “Mini‐mental state”. A practical method for grading the cognitive state of patients for the clinician publication-title: J Psychiatr Res – volume: 260 start-page: 211 year: 2006 end-page: 223 article-title: Cardiovascular disease and Alzheimer's disease: common links publication-title: J Intern Med – volume: 77 start-page: 803 year: 2003 end-page: 808 article-title: Cognitive decline and fatty acid composition of erythrocyte membranes—The EVA study publication-title: Am J Clin Nutr – volume: 42 start-page: 1011 year: 2007 end-page: 1024 article-title: Bioequivalence of docosahexaenoic acid from different algal oils in capsules and in a DHA‐fortified food publication-title: Lipids – volume: 62 start-page: 275 year: 2004 end-page: 280 article-title: Dietary intake of fatty acids and fish in relation to cognitive performance at middle age publication-title: Neurology – volume: 63 start-page: 1153 year: 2008 end-page: 1160 article-title: Effect of dietary n‐3 polyunsaturated fatty acids on brain lipid fatty acid composition, learning ability, and memory of senescence‐accelerated mouse publication-title: J Gerontol A Biol Sci Med Sci – article-title: USDA, Agricultural Research Service, 2007 – volume: 11 start-page: 381 year: 2006 end-page: 387 article-title: DHA and cognitive function in the elderly: a systematic review of the literature publication-title: Res Pract Alzheimer's Dis – volume: 862 start-page: 180 year: 2000 end-page: 186 article-title: Docosahexaenoic acid (DHA) improves the age‐related impairment of the coupling mechanism between neuronal activation and functional cerebral blood flow response: a PET study in conscious monkeys publication-title: Brain Res – volume: 67 start-page: 121 year: 2002 end-page: 130 article-title: Long‐term potentiation in aged rats is restored when the age‐related decrease in polyunsaturated fatty acid concentration is reversed publication-title: Prostaglandins Leukot Essent Fatty Acids – volume: 12 start-page: 265 year: 2001 end-page: 280 article-title: Early detection and differential diagnosis of Alzheimer's disease and depression with neuropsychological tasks publication-title: Dement Geriatr Cogn Disord – volume: 17 start-page: 37 year: 1982 end-page: 49 article-title: Development and validation of a geriatric depression screening scale: a preliminary report publication-title: J Psychiatr Res – volume: 71 start-page: 430 year: 2008 end-page: 438 article-title: Effect of fish oil on cognitive performance in older subjects: a randomized, controlled trial publication-title: Neurology – volume: 31 start-page: 746 year: 2007 end-page: 751 article-title: Automated Neuropsychological Test Battery (CANTAB) in mild cognitive impairment and in Alzheimer's disease publication-title: Prog Neuropsychopharmacol Biol Psychiatry – volume: 63 start-page: 1545 year: 2006 end-page: 1550 article-title: Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study publication-title: Arch Neurol – ident: e_1_2_6_43_2 doi: 10.1111/j.1365-2796.2006.01687.x – ident: e_1_2_6_20_2 doi: 10.1001/archneur.63.10.1402 – ident: e_1_2_6_2_2 – ident: e_1_2_6_14_2 doi: 10.1016/S0006-8993(00)02115-6 – ident: e_1_2_6_44_2 doi: 10.1161/01.HYP.34.2.253 – ident: e_1_2_6_11_2 doi: 10.1016/S0163-7827(00)00017-5 – ident: e_1_2_6_16_2 doi: 10.1523/JNEUROSCI.4225-04.2005 – ident: e_1_2_6_39_2 doi: 10.1161/CIRCULATIONAHA.108.191261 – volume: 60 start-page: 146 year: 2006 ident: e_1_2_6_24_2 article-title: Mild memory impairment in healthy older adults is distinct from normal aging publication-title: Brain Cogn doi: 10.1016/j.bandc.2005.10.004 – volume-title: Diagnostic and Statistical Manual of Mental Disorders year: 1994 ident: e_1_2_6_27_2 – ident: e_1_2_6_37_2 doi: 10.1007/s11745-007-3098-5 – ident: e_1_2_6_32_2 – ident: e_1_2_6_31_2 doi: 10.1097/MJT.0b013e31817fe2be – ident: e_1_2_6_34_2 doi: 10.1097/01.wad.0000213873.25053.2b – ident: e_1_2_6_38_2 – ident: e_1_2_6_36_2 doi: 10.1016/0022-3956(82)90033-4 – ident: e_1_2_6_42_2 doi: 10.1159/000051269 – ident: e_1_2_6_3_2 doi: 10.7326/0003-4819-148-6-200803180-00005 – ident: e_1_2_6_5_2 doi: 10.1093/ajcn/85.4.1103 – volume: 11 start-page: 381 year: 2006 ident: e_1_2_6_8_2 article-title: DHA and cognitive function in the elderly: a systematic review of the literature publication-title: Res Pract Alzheimer's Dis – ident: e_1_2_6_21_2 doi: 10.1016/j.jalz.2008.07.003 – ident: e_1_2_6_33_2 doi: 10.1080/13607860410001709665 – ident: e_1_2_6_41_2 doi: 10.1159/000074081 – volume: 5 start-page: 266 year: 1994 ident: e_1_2_6_22_2 article-title: Cambridge Neuropsychological Test Automated Battery (CANTAB): a factor analytic study of a large sample of normal elderly volunteers publication-title: Dementia – volume: 83 year: 2006 ident: e_1_2_6_30_2 article-title: Distribution, interconversion, and dose response of n‐3 fatty acids in humans publication-title: Am J Clin Nutr doi: 10.1093/ajcn/83.6.1467S – ident: e_1_2_6_15_2 doi: 10.1093/gerona/63.11.1153 – ident: e_1_2_6_28_2 doi: 10.1080/87565648609540348 – ident: e_1_2_6_18_2 doi: 10.1212/01.wnl.0000324268.45138.86 – ident: e_1_2_6_13_2 doi: 10.1054/plef.2002.0408 – ident: e_1_2_6_10_2 doi: 10.1212/01.WNL.0000103860.75218.A5 – ident: e_1_2_6_4_2 doi: 10.1093/ajcn/77.4.803 – ident: e_1_2_6_29_2 – ident: e_1_2_6_12_2 doi: 10.1007/s11745-001-0805-6 – ident: e_1_2_6_19_2 doi: 10.1016/j.pnpbp.2008.05.015 – ident: e_1_2_6_23_2 doi: 10.1017/S003329170200524X – ident: e_1_2_6_17_2 doi: 10.1523/JNEUROSCI.0055-07.2007 – ident: e_1_2_6_25_2 doi: 10.1002/ana.10105 – ident: e_1_2_6_40_2 doi: 10.1017/S1355617702811067 – ident: e_1_2_6_9_2 doi: 10.1001/archneur.60.7.940 – ident: e_1_2_6_6_2 doi: 10.1007/s11745-000-0646-3 – ident: e_1_2_6_7_2 doi: 10.1001/archneur.63.11.1545 – ident: e_1_2_6_26_2 doi: 10.1016/j.pnpbp.2007.01.011 – ident: e_1_2_6_35_2 doi: 10.1016/0022-3956(75)90026-6 |
| SSID | ssj0040815 |
| Score | 2.4820964 |
| Snippet | Abstract Background Docosahexaenoic acid (DHA) plays an important role in neural function. Decreases in plasma DHA are associated with cognitive decline in... Docosahexaenoic acid (DHA) plays an important role in neural function. Decreases in plasma DHA are associated with cognitive decline in healthy elderly adults... Background Docosahexaenoic acid (DHA) plays an important role in neural function. Decreases in plasma DHA are associated with cognitive decline in healthy... Background Docosahexaenoic acid (DHA) plays an important role in neural function. Decreases in plasma DHA are associated with cognitive decline in healthy... |
| SourceID | proquest pubmed crossref wiley elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 456 |
| SubjectTerms | Acids Aged aging Aging - drug effects Aging - psychology Alzheimer's disease clinical trial cognition Cognition Disorders - diagnosis Cognition Disorders - metabolism Cognition Disorders - prevention & control Cognitive impairment Dementia - diagnosis Dementia - drug therapy Dementia - prevention & control docosahexaenoic acid Docosahexaenoic Acids - administration & dosage Docosahexaenoic Acids - adverse effects Double-Blind Method Elderly people Female Humans Learning Learning Disorders - diagnosis Learning Disorders - metabolism Learning Disorders - prevention & control Male Memory Memory Disorders - diagnosis Memory Disorders - metabolism Memory Disorders - prevention & control Middle Aged Neurology Nootropic Agents - administration & dosage Nootropic Agents - adverse effects nutrition omega-3 fatty acid |
| Title | Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline |
| URI | https://www.clinicalkey.es/playcontent/1-s2.0-S1552526010000403 https://dx.doi.org/10.1016/j.jalz.2010.01.013 https://onlinelibrary.wiley.com/doi/abs/10.1016%2Fj.jalz.2010.01.013 https://www.ncbi.nlm.nih.gov/pubmed/20434961 https://www.proquest.com/docview/799785603 https://www.proquest.com/docview/822497863 |
| Volume | 6 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LatwwFBUhq25KS1_TF1p0V9yxRw9b3aWhIQxtN21g6EbocU0dgh3iBEoX_fbeK8uGEDqUgjHGSNiSrq6O8TlHjL3BsIC2VU0BUvlCmhgLh4NRqDpGE0KUzpDA-fMXfXomtzu1O2DHsxaGaJU59085PWXrfGede3N92XXrr2QepsgRK-Hc5PgpZU1R_u73QvOQuOSp5Jmq6KNLl1k4M3G8zt3Fr0zvqvAQf1uc7oLP21g2LUYnD9j9jCL50fSiD9kB9I_Y7gPmrckQgmeaBh9aHocwjO4H_HTQD13gLnSRDz3PxCG86nqOWaVIshaIfGEU8QgknITH7Ozk47fj0yJvnFAERGei0G2jQNQOcPp6UhnoFoGSqwHAbUKQIupoXNOWTW2cMMGT65sQXgAYMG0jnrDDfujhGeMtbFzZ-BqUCFIH7VTwwsUKQbl3lYcVq-YesyG7itPmFhd2po-dW-plS71sywoPsWJvlzqXk6fG3tL1PBB2VotifoMxT7bRVnbc2NLeCYgVU0vNWzFlcbnY-0Q-j7fFyUZ_UFwPw81oa4Mf3YgR9xQhVi4W0ljk6RQqSxtJhiyNrlbsfYqdf2i8Pfr0fbvFE90jO0Dx_D8b9YLdS8SHJKN8yQ6vr27gFeKpa_86TZg_VhAbKA |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LatwwFBUhWbSb0tLX9JFq0V1xxx49bHWXhITpdJJNExi6EXpcU4dghzqB0kW_vVeybAihQykYY4yMLeneq2N8zjEh7zEsoK5FlQEXNuPK-8zgZGSi9F4557lRQeB8eiaXF3y1EZsdcjRqYQKtMtX-oabHap3OzNNozq-bZv41mIeJ4IgVcW5w_NzjmL4hOz_-nngeHNc8EU1TRXjrknlSzgwkr0tz9Svxuwrc2N9Wp_vo8y6YjavRyWPyKMFIejA86ROyA-1TsjnEwjU4QtDE06BdTX3nut58h58G2q5x1LjG066liTmER01LsaxkUdcCnk6UIuohKCfhGbk4OT4_WmbpzwmZQ3jGMllXAlhpAPPXBpmBrBEpmRIAzMI5zrz0ylR1XpXKMOVssH1jzDIABaqu2HOy23YtvCS0hoXJK1uCYI5LJ41wlhlfICq3prAwI8U4YtolW_Hwd4srPfLHLnUYZR1GWecFbmxGPkzXXA-mGltbl-NE6FEuigUO-pRtvS50v9C5vhcRMyKmK-8Elcb1Yusd6TjfGrMtfEIxLXS3vS4VvnUjSNzSJNBysZHEJi-GUJn6GHTIXMliRj7F2PmHzuuD9bfVCnfhXPADZK_-s1PvyIPl-elarz-ffXlNHkYWRNRUviG7Nz9u4S2Cqxu7H5PnD4HOHkM |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Beneficial+effects+of+docosahexaenoic+acid+on+cognition+in+age-related+cognitive+decline&rft.jtitle=Alzheimer%27s+%26+dementia&rft.au=Yurko-Mauro%2C+Karin&rft.au=McCarthy%2C+Deanna&rft.au=Rom%2C+Dror&rft.au=Nelson%2C+Edward+B&rft.date=2010-11-01&rft.issn=1552-5279&rft.eissn=1552-5279&rft.volume=6&rft.issue=6&rft.spage=456&rft_id=info:doi/10.1016%2Fj.jalz.2010.01.013&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F15525260%2FS1552526010X00073%2Fcov150h.gif |